The FDA on November 8, 2019 approved REBLOZYL® for treatment of anemia in adult patients with beta Thalassemia who require regular red blood cell transfusions. REBLOZYL® is a product of Celgene Corp.
Other Pages – Bottom Ad
Advertisement
Subscribe
Other Pages – Top Ad
Advertisement